BioSpace News Archive

Thirty-eight abstracts underscore AbbVie’s commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private placement of 15,000 shares of a newly created Series B Non-Voting Convertible Preferred Stock

Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021.

NANO-X IMAGING LTD (" Nanox " or the " Company ,” Nasdaq : NNOX) will report its results for the third quarter ended September 30, 2021 before market on Wednesday, November 17, 2021.

IceCure Medical Ltd. announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.

PLx Pharma Inc., is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 13,000 shares of G1’s common stock to one employee under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, and an aggregate of 48,600 shares of G1’s common stock to one employee under the previously-announced G1 Therapeutics, Inc.

Akeso, Inc. announces that AK112, the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China to initiate a phase II clinical trial for monotherapy or combined chemotherapy neoadjuvant/adjuvant therapy of resectable non-small cell lung cancer.

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it has priced an underwritten public offering to sell 35,715,000 shares of common stock at a public offering price of $3.50 per share.

Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces publication a head-of-print in the Annals of Surgery of the “NEXUS Arch Multicenter Study Evaluating the Initial Experience with a Novel Aortic Arch Stent Graft System” by Planer et al.